https://mindmedicinelaw.com/briefing/living-meta-analysis-and-open-data-on-mdma-therapy-for-ptsd-20261011-49193The Psychedelic Journalen2026-10-12T15:04:18.844299+00:00Living Meta-Analysis and Open Data on MDMA Therapy for PTSDmdma-assisted therapy, ptsd, systematic review, meta-analysis, open data, randomized controlled trials, maps, evidence certainty, regulatory policy, psychedelic researchhttps://mindmedicinelaw.com/briefing/ketamine-liability-concerns-legal-pressures-on-u-s-clinics-20261011-49143The Psychedelic Journalen2026-10-11T22:04:30.662819+00:00Ketamine Liability Concerns: Legal Pressures on U.S. Clinicsketamine liability, psychedelic law, ketamine clinics, off-label use, malpractice risk, insurance coverage, standard of care, psychedelic policy, clinical guidelineshttps://mindmedicinelaw.com/briefing/psychedelics-and-sleep-architecture-systematic-review-insights-20261010-48890The Psychedelic Journalen2026-10-11T15:04:44.626535+00:00Psychedelics and Sleep Architecture: Systematic Review Insightspsychedelics, sleep architecture, REM sleep, psilocybin, LSD, ayahuasca, clinical trials, sleep disruption, neuroplasticity, therapeutic mechanismshttps://mindmedicinelaw.com/briefing/swedish-cannabis-use-underestimated-implications-for-policy-reform-20261009-48892The Psychedelic Journalen2026-10-11T15:06:43.224558+00:00Swedish Cannabis Use Underestimated: Implications for Policy Reformcannabis use prevalence, sweden drug policy, cannabis use disorder, survey methodology, healthcare needs, decriminalization impact, public health surveillance, psychedelic policy implicationshttps://mindmedicinelaw.com/briefing/nicotine-s-amplification-of-fentanyl-dopamine-effects-implications-for-oud-risk-20261009-48899The Psychedelic Journalen2026-10-11T15:06:28.201852+00:00Nicotine’s Amplification of Fentanyl Dopamine Effects: Implications for OUD Risknicotine, fentanyl, dopamine transmission, dorsal lateral striatum, opioid use disorder, polysubstance use, addiction neuroscience, public health policy, clinical trialshttps://mindmedicinelaw.com/briefing/psychedelics-in-neurosurgery-promise-evidence-gaps-and-translational-barriers-20261009-48878The Psychedelic Journalen2026-10-11T15:05:39.020236+00:00Psychedelics in Neurosurgery: Promise, Evidence Gaps, and Translational Barrierspsychedelics in neurosurgery, esketamine perioperative use, psilocybin cancer distress, neuroplasticity, clinical trial design, safety barriers, regulatory approval, perioperative care, pain management, neurorehabilitationhttps://mindmedicinelaw.com/briefing/il-6-sgp130-trans-signaling-a-new-mechanism-in-trd-pathogenesis-20261009-48900The Psychedelic Journalen2026-10-11T15:05:21.743873+00:00IL-6 sgp130 Trans-signaling: A New Mechanism in TRD Pathogenesisil-6 trans-signaling, sgp130 buffer, treatment-resistant depression, immunopsychiatry, biomarker stratification, precision psychiatry, sgp130fc, clinical trial design, psychedelic-assisted therapy, neuroinflammationhttps://mindmedicinelaw.com/briefing/germany-s-dzpg-model-systems-a-new-era-for-mechanistic-mental-health-research-20261009-48902The Psychedelic Journalen2026-10-11T15:05:02.836143+00:00Germany's DZPG Model Systems: A New Era for Mechanistic Mental Health Researchdzpg, germany, model systems, mental health research, psychedelic research, animal models, ipsc, high-throughput screening, translational science, public involvementhttps://mindmedicinelaw.com/briefing/adverse-psychedelic-reactions-links-to-psychopathology-in-naturalistic-use-20261008-48861The Psychedelic Journalen2026-10-11T15:05:57.430147+00:00Adverse Psychedelic Reactions: Links to Psychopathology in Naturalistic Usepsychedelic adverse reactions, psychopathology, naturalistic use, harm reduction, public health policy, MDMA risks, contextual factors, user motivation, longitudinal research, screening protocolshttps://mindmedicinelaw.com/briefing/lsd-s-effects-on-cortical-dynamics-mechanistic-insights-for-policy-and-research-20261007-48968The Psychedelic Journalen2026-10-11T15:06:13.596749+00:00LSD’s Effects on Cortical Dynamics: Mechanistic Insights for Policy and Researchlsd, cortical dynamics, fractal dimension, brain rhythms, psychedelic research, biomarkers, clinical trials, regulatory policy, neuroimaging, mechanistic evidence